Taro Pharma (TARO) Posts Inline Q4 Breakeven Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Taro Provides Results for Year Ended March 31, 2015
May 26, 2015 6:44 PM EDTNet Sales Increases 14%, Operating Income and E.P.S. Up 23% and 39%, respectively
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and year ended March 31, 2015.
Quarter ended March 31, 2015 Highlights - compared to March 31, 2014
Net sales of $244.2 million, increased $57.0 million, or 30.5%, on flat volumes Gross profit, as a percentage of net sales, was 81.8%, compared to 75.5% an increase of $58.3 million or 41.2% Research and development expenses increased $10.7 million to $23.9 million... More